Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 3:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 4,084 matching trials from the live ClinicalTrials.gov search.
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Eplerenone and IOP in Healthy Adults

NCT07795762
Conditions
Intraocular Pressure (IOP), Healthy Adult
Interventions
Eplerenone, Microcrystalline Cellulose NF (placebo)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Stage II Angioimmunoblastic T-cell Lymphoma, Stage II Enteropathy-Associated T-Cell Lymphoma, Stage III Angioimmunoblastic T-cell Lymphoma, Stage III Enteropathy-Associated T-Cell Lymphoma, Stage IV Angioimmunoblastic T-cell Lymphoma, Stage IV Enteropathy-Associated T-Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Lenalidomide, Peripheral Blood Stem Cell Transplantation, Prednisone, Vincristine Sulfate
Procedure · Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
8
States / cities
Duarte, California • Palo Alto, California • Aurora, Colorado + 5 more
Terminated Phase 1Phase 2 Interventional Results available

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

NCT02928029
Conditions
Multiple Myeloma
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Encinitas, California • Winston-Salem, North Carolina • Seattle, Washington
Conditions
Plasma Cell Myeloma Refractory
Interventions
Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Glendale, California
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Itacitinib, Placebo, Prednisone, Methylprednisolone
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
49
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 38 more
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Acalabrutinib, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Tafasitamab, Vincristine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell
Interventions
Alemtuzumab (Campath), EPOCH
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
17 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Friedreich Ataxia
Interventions
Methylprednisolone
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Multiple Myeloma
Interventions
ASP7487, Velcade, Dexamethasone
Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia • Chicago, Illinois
Conditions
Lumbar Facet Syndrome
Interventions
Cooled Radiofrequency Ablation of Medial Branch Nerves versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome
Procedure
Lead sponsor
University of Utah
Other
Eligibility
21 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Phase 2 Interventional Accepts healthy volunteers

AFTER: Altering Fat Through Estrogen and Raloxifene

NCT00149604
Conditions
Postmenopause
Interventions
conjugated estrogens, Raloxifene, exercise plus mild caloric restriction for weight loss
Drug · Behavioral
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years to 70 Years · Female only
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Diabetes (DM)
Interventions
Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone, Dextrose 20% solution
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Community Acquired Respiratory Disease Syndrome
Interventions
Inactive Substance, Methylprednisolone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
29
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 26 more
Conditions
Pain Management
Interventions
Dexamethasone 8mg, Placebo
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Lymphoma, Non-Hodgkin
Interventions
Cyclophosphamide, BCNU, Etoposide, Filgrastim, Antithymocyte globulin, Cyclosporine, Mycophenolate mofetil, Rituximab, Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation, CD34+ Cells, Solu-Medrol
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Stanford, California
Conditions
Psoriasis Vulgaris
Interventions
0.01% Halobetasol, 0.045% Tazarotene, 0.05% Clobetasol Propionate
Drug
Lead sponsor
Dermatology Consulting Services, PLLC
Network
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
High Point, North Carolina
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostate Cancer Metastatic
Interventions
Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log, Low-fat meal
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Calaspargase Pegol-mknl, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Pharmacological Study, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 30 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • Palo Alto, California + 22 more
Conditions
Diabetes Mellitus, Type I
Interventions
islets
Drug
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Miami, Florida
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions
Alemtuzumab, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Etoposide Phosphate, Filgrastim, Fludarabine Phosphate, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Laboratory Biomarker Analysis, Leucovorin Calcium, Melphalan, Mercaptopurine, Methotrexate, Pegfilgrastim, Pharmacological Study, Tacrolimus, Vincristine Sulfate
Biological · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
101
States / cities
Palo Alto, California • Aurora, Colorado • Boulder, Colorado + 68 more
Completed Not applicable Interventional Results available

Vitamin D in HIV-Infected Patients on HAART

NCT01250899
Conditions
Vitamin D Deficiency, HIV
Interventions
Vitamin D
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Lymphoma
Interventions
bleomycin sulfate, Stanford V regimen, doxorubicin hydrochloride, etoposide, mechlorethamine hydrochloride, prednisone, vinblastine sulfate, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
16 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Stanford, California
Conditions
Low Back Pain, Radiating Pain
Interventions
Entonox, Oxygen
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio